FluidForm Bio Announces Promising Results for Type 1 Diabetes Treatment at Medical Conferences

Strategic Insights -

FluidForm Bio, a leader in cell therapies for chronic diseases, has presented new data demonstrating the efficacy of its FRESH 3D bioprinted human islet subcutaneous scaffolds in restoring normoglycemia in SCID Beige mice. The company's FRESH platform has shown the potential to overcome shortcomings of current transplantation methodologies, promoting rapid revascularization and engraftment of islet scaffolds without a fibrotic host response. The results were presented at the 20th World Congress of the International Pancreas & Islet Transplant Association (IPITA) in Pisa, Italy, and the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, Illinois.

Key Takeaways:

  • FluidForm's FRESH 3D bioprinted human islet scaffolds have demonstrated six-month efficacy in restoring normoglycemia in SCID Beige mice.
  • The FRESH platform promotes rapid revascularization and engraftment of islet scaffolds without a fibrotic host response.
  • The FRESH platform has shown improved outcomes compared to traditional islet cell injections, with normoglycemia achieved in approximately three weeks.
  • FluidForm's lead program is an islet cell therapy for type 1 diabetes, which offers a transformative advancement in diabetes treatment.
  • The company's FRESH platform has overcome many limitations of current technologies, offering a more effective, durable, and patient-friendly therapy.
  • FluidForm's approach to islet cell replacement therapy presents a new hope for individuals with diabetes.

Statistics:

  • 13 diabetic SCID Beige mice received subcutaneous FRESH scaffold implants, while 3 received subcutaneous islet injections.
  • 100% of mice implanted with FRESH scaffolds demonstrated revascularization of human islets and robust engraftment without a fibrotic response at day 14.
  • Scaffold histology at day 97 displayed host vessel infiltration in the collagen-rich neotissue matrix around and within the transplanted human islet.
  • The FRESH scaffolds restored euglycemia in diabetic SCID mice for up to 180 days.
  • 100% of controls that received islet cell injections remained diabetic, while diabetic SCID Beige mice that received FRESH printed human islet scaffolds achieved normoglycemia in approximately three weeks.

Sources:

  • GlobeNewswire: "FluidForm Bio(TM) Announces Promising Results for Type 1 Diabetes Treatment at Medical Conferences" (2025-07-09)
  • FluidForm Bio's website: "FRESH 3D Bioprinting Technology Platform"
  • American Diabetes Association (ADA) 85th Scientific Sessions: "Restoration of Normoglycemia via Subcutaneous Transplantation of Islets in FRESH 3D Printed ECM-Based Scaffolds"
  • 20th World Congress of the International Pancreas & Islet Transplant Association (IPITA): "Fresh 3D Printed ECM-Based Scaffolds Support Engraftment of Subcutaneously Transplanted Islets"